United States - English - NLM (National Library of Medicine)

mylan institutional llc - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine 1 mg in 1 ml - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine injection is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine 1 mg in 1 ml - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine injection is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

onco therapies limited - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine 1 mg in 1 ml

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine injection, usp is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine injection, usp is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc. - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine 1 mg in 1 ml

Canada - English - Health Canada

fresenius kabi canada ltd - cladribine - solution - 1mg - cladribine 1mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cladribine, quantity: 10 mg - tablet, uncoated - excipient ingredients: hydroxypropylbetadex; sorbitol; magnesium stearate - mavenclad is indicated for the treatment of relapsing-remitting multiple sclerosis (rrms) to reduce the frequency of clinical relapses and to delay the progression of physical disability.,following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. re-initiation of therapy after year 4 has not been studied.

Canada - English - Health Canada

generic medical partners inc - cladribine - solution - 1mg - cladribine 1mg - antineoplastic agents